Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma

Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma; A Randomized Controlled Comparative Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07560332

Enrollment

Registered

2026-05-01

Start date

2025-01-01

Completion date

2026-01-01

Last updated

2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile Hemangioma (IH)

Keywords

propranolol, timolol, carbon dioxide laser, infantile hemangioma

Brief summary

To assess and compare the efficacy of systemic beta-blocker therapy with the efficacy and safety of fractional carbon dioxide laser-assisted delivery of a topical beta-blocker solution in the treatment of infantile hemangioma.

Interventions

DRUGPropranolol 1

oral propranolol is given daily in a dose of 1 to 2 mgékg daily for 3 months

DEVICEFractional CO2 laser with topical timolol

Weekly sessions were performed followed by application of timolol daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Months to 12 Years

Healthy volunteers

Inclusion criteria

, aged 1 month to 12 years \- presenting with superficial, deep, mixed, or proliferating IH.

Exclusion criteria

* other cutaneous or systemic infections * chronic systemic diseases * known allergy to topical timolol maleate * contraindications to laser or beta-blocker therapy * IH involving mucosal or perimucosal sites * and a history of adverse reactions to laser therapy or keloid tendency.

Design outcomes

Primary

Measure	Time frame
Improvement of global assessment score of infantile hemangioma	3 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026